Carey Hwang

1.9k total citations
49 papers, 1.2k citations indexed

About

Carey Hwang is a scholar working on Infectious Diseases, Virology and Hepatology. According to data from OpenAlex, Carey Hwang has authored 49 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Infectious Diseases, 29 papers in Virology and 18 papers in Hepatology. Recurrent topics in Carey Hwang's work include HIV/AIDS drug development and treatment (32 papers), HIV Research and Treatment (29 papers) and Hepatitis C virus research (18 papers). Carey Hwang is often cited by papers focused on HIV/AIDS drug development and treatment (32 papers), HIV Research and Treatment (29 papers) and Hepatitis C virus research (18 papers). Carey Hwang collaborates with scholars based in United States, France and United Kingdom. Carey Hwang's co-authors include Vinay K. Pathak, Evguenia S. Svarovskaia, George J. Hanna, Richard Bertz, Jean‐Michel Molina, Neelanjana Ray, Dennis M. Grasela, Marc Bifano, Hamza Kandoussi and Sushma Kumar and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Clinical Infectious Diseases.

In The Last Decade

Carey Hwang

49 papers receiving 1.2k citations

Peers

Countries citing papers authored by Carey Hwang

Since Specialization

Citations

This map shows the geographic impact of Carey Hwang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carey Hwang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carey Hwang more than expected).

Fields of papers citing papers by Carey Hwang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carey Hwang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carey Hwang. The network helps show where Carey Hwang may publish in the future.

Co-authorship network of co-authors of Carey Hwang

This figure shows the co-authorship network connecting the top 25 collaborators of Carey Hwang. A scholar is included among the top collaborators of Carey Hwang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carey Hwang. Carey Hwang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D 2025 ·New England Journal of Medicine ·Tarik Asselah, Michael A. Chattergoon, Alina Jucov, Adrian Streinu‐Cercel, Pietro Lampertico, Heiner Wedemeyer, (unknown), Edward Gane, (unknown), (unknown), (unknown), Grégory Camus, Yimeng Lu, (unknown), Carey Hwang, (unknown), Kosh Agarwal	1
2	VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study 2024 ·The Lancet. Gastroenterology & hepatology ·Man‐Fung Yuen, Young‐Suk Lim, Ki Tae Yoon, (unknown), Jeong Heo, Pisit Tangkijvanich, Won Young Tak, (unknown), D. C. Cloutier, Shenghua Mao, (unknown), Andrea L. Cathcart, Sneha Gupta, Carey Hwang, Edward Gane	31
3	OS-127 Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants 2024 ·Journal of Hepatology ·Tarik Asselah, Adrian Streinu‐Cercel, Alina Jucov, Edward Gane, Heiner Wedemeyer, Pietro Lampertico, Michael A. Chattergoon, Pan Wu, Sonia Maciejewski, (unknown), (unknown), (unknown), Carey Hwang, Kosh Agarwal	5
4	Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes 2023 ·Clinical Infectious Diseases ·Marion G. Peters, Man‐Fung Yuen, Norah A. Terrault, John Fry, Pietro Lampertico, Ed Gane, Carey Hwang, Luisa M. Stamm, (unknown), Mala K. Maini, Patricia Méndez, Isabelle Lonjon‐Domanec, Thomas Berg, Su Wang, Poonam Mishra, Eric Donaldson, Stephanie Buchholz, Veronica Miller, Oliver Lenz	5
5	Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial 2021 ·The Lancet HIV ·Jean‐Michel Molina, Yazdan Yazdanpanah, (unknown), Christopher Bettacchi, (unknown), Edwin DeJesus, Stephanie O. Klopfer, Anjana Grandhi, Karen Eves, Michael Robertson, (unknown), Carey Hwang, George J. Hanna, Peter Sklar	33
6	Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine 2021 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jean‐Michel Molina, Yazdan Yazdanpanah, (unknown), Christopher Bettacchi, (unknown), Stephanie O. Klopfer, Anjana Grandhi, Karen Eves, (unknown), Michael Robertson, Carey Hwang, George J. Hanna, (unknown)	15
7	Islatravir safety analysis through week 48 from a phase 2 trial in treatment naive adults with HIV-1 infection 2020 ·Journal of the International AIDS Society ·Edwin DeJesus, Jean‐Michel Molina, Yazdan Yazdanpanah, (unknown), Christopher Bettacchi, (unknown), Stephanie O. Klopfer, Anjana Grandhi, Karen Eves, Michael Robertson, Peter Sklar, Carey Hwang, George J. Hanna, (unknown)	2
8	Islatravir in combination with doravirine maintains HIV-1 viral suppression through 96 weeks 2020 ·Journal of the International AIDS Society ·Jean‐Michel Molina, Yazdan Yazdanpanah, (unknown), Christopher Bettacchi, (unknown), (unknown), Stephanie O. Klopfer, Anjana Grandhi, Karen Eves, (unknown), Michael Robertson, Carey Hwang, George J. Hanna, (unknown)	8
9	Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus–1: An Integrated Safety Analysis 2019 ·Clinical Infectious Diseases ·Melanie Thompson, Chloe Orkin, Jean‐Michel Molina, Paul E. Sax, Pedro Cahn, Kathleen Squires, Xia Xu, Anthony Rodgers, Sushma Kumar, Hedy Teppler, Élizabeth Martin, George J. Hanna, Carey Hwang	10
10	Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate 2019 ·Antimicrobial Agents and Chemotherapy ·Wayne Greaves, Hong Wan, Ka Lai Yee, (unknown), Pavan Vaddady, Carey Hwang	3
11	Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial 2019 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Margaret Johnson, Princy Kumar, Jean‐Michel Molina, Giuliano Rizzardini, Pedro Cahn, Markus Bickel, Josep Mallolas, Yan Zhou, (unknown), Sushma Kumar, Peter Sklar, George J. Hanna, Carey Hwang, Wayne Greaves, (unknown)	64
12	LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial 2018 ·Open Forum Infectious Diseases ·Princy Kumar, Margaret Johnson, Jean‐Michel Molina, Giuliano Rizzardini, Pedro Cahn, Markus Bickel, Josep Mallolas, Yan Zhou, (unknown), Sushma Kumar, Peter Sklar, George J. Hanna, Carey Hwang, Wayne Greaves	4
13	Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial 2018 ·Clinical Infectious Diseases ·Chloe Orkin, Kathleen Squires, Jean‐Michel Molina, Paul E. Sax, Wing-Wai Wong, Otto Sussmann, Richard Kaplan, Lisa Lupinacci, Anthony Rodgers, Xia Xu, Gina Lin, Sushma Kumar, Peter Sklar, Bach‐Yen Nguyen, George J. Hanna, Carey Hwang, Elizabeth A. Martin, (unknown)	107
14	Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy 2017 ·The Journal of Infectious Diseases ·Cynthia L. Gay, Ronald J. Bosch, Justin Ritz, Jason Hataye, Evgenia Aga, Randall L. Tressler, Stephen W. Mason, Carey Hwang, Dennis M. Grasela, Neelanjana Ray, (unknown), John M. Coffin, Edward P. Acosta, Richard A. Koup, John W. Mellors, Joseph J. Eron	180
15	An Open-Label Investigation into Drug–Drug Interactions Between Multiple Doses of Daclatasvir and Single-Dose Cyclosporine or Tacrolimus in Healthy Subjects 2015 ·Clinical Drug Investigation ·Marc Bifano, (unknown), Carey Hwang, Hamza Kandoussi, (unknown), Richard Bertz	28
16	Evaluation of drug‐drug interaction between daclatasvir and methadone or buprenorphine/naloxone 2014 ·Journal of the International AIDS Society ·Τushar Garimella, (unknown), Wen‐Lin Luo, Philip Wastall, Hamza Kandoussi, Michael DeMicco, Douglas Bruce, Carey Hwang, Richard Bertz, Marc Bifano	5
17	Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068 2013 ·Journal of Antimicrobial Chemotherapy ·Nannan Zhou, Beata Nowicka-Sans, Brian McAuliffe, Neelanjana Ray, (unknown), Hua Fang, Fan Li, Matthew D. Healy, David R. Langley, Carey Hwang, Max Lataillade, George J. Hanna, Mark Krystal	55
18	Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV NRTI, in Treatment-Experienced HIV-1–Infected Subjects 2013 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Laurent Cotte, P. Dellamonica, François Raffi, Yazdan Yazdanpanah, Jean‐Michel Molina, François Boué, Yasuo Urata, (unknown), Li Zhu, Ih Chang, Richard Bertz, George J. Hanna, Dennis M. Grasela, Carey Hwang	12
19	Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068 2013 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Neelanjana Ray, Carey Hwang, Matthew D. Healy, Jeannette M. Whitcomb, Max Lataillade, Megan Wind‐Rotolo, Mark Krystal, George J. Hanna	39
20	In VitroCross-Resistance Profile of Nucleoside Reverse Transcriptase Inhibitor (NRTI) BMS-986001 against Known NRTI Resistance Mutations 2013 ·Antimicrobial Agents and Chemotherapy ·Zhufang Li, Brian Terry, (unknown), (unknown), Carol Deminie, Beatrice Minassian, Beata Nowicka-Sans, Yongnian Sun, Ira B. Dicker, Carey Hwang, Max Lataillade, George J. Hanna, Mark Krystal	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact